<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613361</url>
  </required_header>
  <id_info>
    <org_study_id>curcumin in nephrotoxicity</org_study_id>
    <nct_id>NCT05613361</nct_id>
  </id_info>
  <brief_title>The Effect of Curcumin Against Colistin-induced Nephrotoxicity</brief_title>
  <official_title>The Effect of Curcumin Against Colistin-induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October 6 University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to investigate the possible nephroprotective effect of curcumin in&#xD;
      critically ill patients receiving colistin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate the possible nephroprotective effect of curcumin when added to&#xD;
      patients infected by MDR Gram-negative bacteria and require intravenous colistin therapy,&#xD;
      curcumin will be given concurrently with colistin and discontinued at the same time as&#xD;
      Colistin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of acute kidney injury</measure>
    <time_frame>Baseline to hospital discharge, an average of 14 days.</time_frame>
    <description>colistin induced nephrotoxicity (CIN) is defined as increase of serum creatinine by 0.3 mg/dL 48 hours after colistin administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute tubular necrosis (ATN)</measure>
    <time_frame>Baseline to hospital discharge, an average of 14 days.</time_frame>
    <description>will be evaluated by fractional excreted sodium (FENa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between the levels of urinary NGAL</measure>
    <time_frame>Baseline to hospital discharge, an average of 14 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Baseline to 30 days post discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of ICU and hospital stays.</measure>
    <time_frame>Baseline to hospital discharge, an average of 14 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Drug-Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group will receive loading dose of colistin intravenously of 9 MIU followed by maintenance doses of 4.5 MIU given every 12 hours and curcumin will be administered as orally or through nasogastric tube at a dose of 2 capsules every 6 hours (1 gm/6 hour)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin</intervention_name>
    <description>added for infection with multi drug resistant bacteria</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>added for the possible nephroprotective effect</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All critically ill adult patients (18-65 years old) who are infected by MDR&#xD;
             Gram-negative bacteria and require intravenous colistin therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving intravenous colistin therapy for &lt; 72 hours.&#xD;
&#xD;
          -  Patients receiving renal replacement therapy (RRT).&#xD;
&#xD;
          -  Patients with diseases that may contribute to renal impairment such as systemic lupus&#xD;
             erythematosus, acute myocardial infarction, cancer, HIV infection,&#xD;
             glucose-6-phosphate-dehydrogenase deficiency, or urinary tract stone.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Known allergy to the study medications.&#xD;
&#xD;
          -  Patients with chronic kidney diseases (creatinine clearance &lt; 60 mg/dL).&#xD;
&#xD;
          -  Elevated total liver enzymes (AST, and ALT) three times above the upper limit of&#xD;
             normal.&#xD;
&#xD;
          -  Patients with acute decompensated heart failure signs and symptoms requiring&#xD;
             intravenous loop diuretics and/or intravenous inotropes and/or ACE inhibitors.&#xD;
&#xD;
          -  Uncontrolled diabetes (Glycosylated hemoglobin (Hb A1C) &gt;8%).&#xD;
&#xD;
          -  Hypotensive patients defined as decrease in blood pressure less than 90/60 mm Hg.&#xD;
&#xD;
          -  Recent use of vitamins with antioxidant properties such as beta carotene, vitamin E,&#xD;
             vitamin C, selenium, or N-acetylcysteine or any other medications known to have&#xD;
             nephroprotective activities.&#xD;
&#xD;
          -  Patients receiving other nephrotoxic drugs at enrollment (e.g., aminoglycosides,&#xD;
             vancomycin, or amphotericin B) or administration of contrast medium within 7 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirmeen A. Sabry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Clinical Pharmacy Faculty of Pharmacy Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maggie M. Abbassi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Clinical Pharmacy Faculty of Pharmacy Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rania El-Husseiny</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Critical Care Medicine, Faculty of Medicine Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alaa M. Hammad</last_name>
    <phone>01000675555</phone>
    <email>alaa.hammad.ph@o6u.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>1133</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaa M Hammad</last_name>
      <phone>01000675555</phone>
      <email>alaa.hammad.ph@o6u.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 5, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Alaa Mohammed Hammad</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

